Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman Sells 60,000 Shares

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 60,000 shares of Inari Medical stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $55.66, for a total transaction of $3,339,600.00. Following the completion of the sale, the director now directly owns 441,233 shares in the company, valued at approximately $24,559,028.78. This represents a 11.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

William Hoffman also recently made the following trade(s):

• On Monday, November 18th, William Hoffman sold 60,000 shares of Inari Medical stock. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00.
• On Tuesday, October 29th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $50.05, for a total value of $2,002,000.00.
• On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.02, for a total value of $1,800,800.00.

Inari Medical Stock Performance

Shares of NARI stock opened at $55.45 on Friday. The company has a market capitalization of $3.25 billion, a PE ratio of -41.07 and a beta of 0.97. Inari Medical, Inc. has a 52-week low of $36.73 and a 52-week high of $66.61. The business’s fifty day moving average is $50.12 and its 200 day moving average is $48.16.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on NARI shares. Oppenheimer started coverage on Inari Medical in a research note on Tuesday. They set an “outperform” rating and a $75.00 price target for the company. Robert W. Baird lifted their target price on shares of Inari Medical from $66.00 to $67.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 29th. Stifel Nicolaus started coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They issued a “hold” rating and a $50.00 price target on the stock. Leerink Partnrs raised shares of Inari Medical to a “hold” rating in a report on Tuesday, September 3rd. Finally, Leerink Partners started coverage on shares of Inari Medical in a report on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 target price on the stock. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $61.80.

Hedge Funds Weigh In On Inari Medical

A number of institutional investors have recently added to or reduced their stakes in NARI. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Inari Medical by 7.7% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,852 shares of the company’s stock worth $234,000 after purchasing an additional 348 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares during the last quarter. Louisiana State Employees Retirement System raised its position in shares of Inari Medical by 2.4% during the 2nd quarter. Louisiana State Employees Retirement System now owns 26,000 shares of the company’s stock valued at $1,252,000 after buying an additional 600 shares in the last quarter. Legato Capital Management LLC purchased a new stake in shares of Inari Medical during the 2nd quarter valued at $397,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Inari Medical by 11.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,463 shares of the company’s stock worth $696,000 after acquiring an additional 1,475 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.